Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand.
The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells.
Involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter
Monomer. Interacts with ERCC6 (PubMed:26030138). Interacts with TPRN; TPRN interacts with a number of DNA damage response proteins, is recruited to sites of DNA damage and may play a role in DNA damage repair (PubMed:23213405)
(Microbial infection) Interacts with SV40 Large T antigen; this interactions allows viral DNA replication
Endothelial cells
No mutation information available.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to OTOP1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 35
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT06797999 | Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma | First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma | PHASE1, PHASE2 | RECRUITING |
| NCT03030417 | Solid Tumors, Lymphoma | Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas | PHASE1 | COMPLETED |
| NCT06619236 | Platinum-resistant Ovarian Cancer | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | PHASE3 | ACTIVE_NOT_RECRUITING |
| NCT00358319 | Malignant Melanoma | Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma | PHASE1, PHASE2 | TERMINATED |
| NCT07444814 | Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | PHASE1 | RECRUITING |
| NCT07360314 | Advanced Solid Tumors | Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | PHASE1 | RECRUITING |
| NCT05579366 | High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | PHASE1, PHASE2 | RECRUITING |
| NCT05178719 | Osteoporosis | Treatment of Osteoporosis - TOP 2-5 Clinical Studies (Pear Control) | NA | COMPLETED |
| NCT06721689 | Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Rhabdomyosarcoma, Refractory Rhabdomyosarcoma | PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors | PHASE1, PHASE2 | RECRUITING |
| NCT01550510 | Stage IV Colorectal Cancer | Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA | PHASE1, PHASE2 | TERMINATED |